Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7564-7568

  Cotrim, Ana Paola ^a   Sowers, Anastasia L ^b   Lodde, Beatrijs M ^a   Vitolo, Joseph M ^a   Kingman, Albert ^a   Russo, Angelo ^b   Mitchell, James B ^b   Baum, Bruce J ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; PLACEBO; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GEL; HEAD AND NECK CANCER; HIGH RISK PATIENT; MOUSE; MOUTH HYGIENE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; SALIVARY GLAND FUNCTION; SALIVATION; XEROSTOMIA;

ANIMALS; CRANIAL IRRADIATION; CYCLIC N-OXIDES; DRUG ADMINISTRATION ROUTES; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C3H; MODELS, ANIMAL; RADIATION-PROTECTIVE AGENTS; SALIVARY GLANDS; SALIVATION; SPIN LABELS; XEROSTOMIA;

EID: 27144458434     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0958     Document Type: Article

References (26)

1. Hill B. Oral cancer facts 2005, http://www. oralcancerfoundation.org.
2. Day GL. Cancer Rates and Risks, online publication. From the Epidemiology and Extramural Programs Branch, Division of Cancer Etiology, National Cancer Institute, Bethesda, Maryland. Available from: http://seer.cancer.gov/ publications/raterisk/risks175.html.
3. Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 2nd ed, In: Lippincott-Raven, editor. Head and neck cancer. Vol. 5. Philadelphia (PA): Lippincott-Raven; 1999. p. 320.
4. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current status and new directions. Oncology 2002;63:2-10.
5. Vissink A, Jansma J, Spijkervet FK, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212.
6. Vissink A, Burlage FR, Spijkervet FK, et al. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:213-25.
7. Nagler RM, Baum BJ. Prophylactic treatment reduces the severity of xerostomia following radiation therapy for oral cavity cancer. Arch Otolaryngol Head Neck Surg 2003;129:247-50.
8. Sodicoff M, Conger AD, Trepper P, et al. Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res 1978;75:317-26.
9. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-45.
10. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003;4:378-81.
11. Schuchter L, Meropol NJ, Winer EP, et al. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol 2003;4:593.
12. Vitolo JM, Cotrim AP, Sowers AL, et al. The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 2004;10:1807-12.
13. van Eyk AD, van der Bijl P. Comparative permeability of various chemical markers through human vaginal and buccal mucosa as well as porcine buccal and mouth floor mucosa. Arch Oral Biol 2004;49:387-92.
14. Chiou WL. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology. J Pharmacokinet Pharmacodyn 2001;28:3-6.
15. Mitchell JB, Russo A, Kuppusamy P, et al. Radiation, radicals, and images. Ann N Y Acad Sci 2000;899:28-43.
16. Xavier S, Yamada K, Samuni AM, et al. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim Biophys Acta 2002;1573:109-20.
17. Matsumoto K, Krishna MC, Mitchell JB. Novel pharmacokinetic measurement using electron paramagnetic resonance spectroscopy and simulation of in vivo decay of various nitroxyl spin probes in mouse blood. J Pharmacol Exp Ther 2004;310:1076-83.
18. Mitchell JB, Yamada K, Devasahayam N, et al. Novel functional imaging for tissue oxygen concentration and redox status. J Nutr 2004;134:3210S.
19. Hahn SM, Tochner Z, Krishna CM, et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 1992;52:1750-3.
20. Cuscela D, Coffin D, Lupton GP, et al. Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J Sci Am 1996;2:273.
21. Metz JM, Smith D, Mick R, et al. A phase I study of topical tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 2004;10:6411-7.
22. Schubert R, Erker L, Barlow C, et al. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet 2004;13:1793-802.
23. Mitchell JB, Xavier S, DeLuca AM, et al. A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med 2003;34:93-102.
24. Erker L, Schubert R, Yakushiji H, et al. Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor. Hum Mol Genet 2005;14:1699-708.
25. Hahn SM, Sullivan FJ, DeLuca AM, et al. Evaluation of tempol radioprotection in a murine tumor model. Free Radic Biol Med 1997;22:1211-6.
26. Mitchell JB, DeGraff W, Kaufman D, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 1991;289:62-70.